$3.57
0.28% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Polypid Ltd Stock price

$3.57
+1.02 40.00% 1M
+0.68 23.53% 6M
+0.53 17.43% YTD
-0.63 15.00% 1Y
-136.23 97.45% 3Y
-566.13 99.37% 5Y
-566.43 99.37% 10Y
-566.43 99.37% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.01 0.28%
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Key metrics

Basic
Market capitalization
$36.4m
Enterprise Value
$35.2m
Net debt
$-1.2m
Cash
$8.0m
Shares outstanding
10.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
425.00
Financial Health
Equity Ratio
30.47%
Return on Equity
-377.41%
ROCE
-657.09%
ROIC
-
Debt/Equity
76.44
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-22.4m
EBIT
$-29.3m
Net Income
$-30.8m | $-19.9m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 14.94%
EBIT
-25.35%
Net Income
-27.18% | 31.38%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.62
FCF per Share
Short interest
4.37%
Employees
59.00
Rev per Employee
$0.00
Show more

Is Polypid Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Polypid Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Polypid Ltd forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Polypid Ltd forecast:

Buy
89%
Hold
11%

Financial data from Polypid Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.43 5.43
9% 9%
-
- Research and Development Expense 24 24
37% 37%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
25% 25%
-
Net Profit -31 -31
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polypid Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polypid Ltd Stock News

Neutral
GlobeNewsWire
11 days ago
PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million....
Neutral
GlobeNewsWire
17 days ago
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future
Neutral
GlobeNewsWire
17 days ago
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future
More Polypid Ltd News

Company Profile

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID–500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Head office Israel
CEO Dikla Akselbrad
Employees 59
Founded 2008
Website www.polypid.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today